Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. (Q53475183)

14 May 2018

title

Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. (English)

1 reference

14 May 2018

1 reference

Mycobacterium szulgai

Mycobacterium szulgai

1 reference

1

1 reference

14 May 2018

Matthijs Janssen

Matthijs Janssen

3

0 references

Dick van Soolingen

8

Dick van Soolingen

1 reference

14 May 2018

6

Petra de Haas

1 reference

14 May 2018

Martin J. Boeree

2

Martin Boeree

1 reference

14 May 2018

Wiel C. M. de Lange

5

Wiel de Lange

1 reference

14 May 2018

P N Richard Dekhuijzen

7

Richard Dekhuijzen

1 reference

14 May 2018

author name string

Erik Ullmann

4

1 reference

14 May 2018

publication date

1 July 2007

1 reference

14 May 2018

Nature Clinical Practice Rheumatology

published in

1 reference

14 May 2018

volume

3

1 reference

14 May 2018

issue

7

1 reference

14 May 2018

page(s)

414-419

1 reference

14 May 2018

Pseudoepidemic due to a unique strain of Mycobacterium szulgai: genotypic, phenotypic, and epidemiological analysis

cites work

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0538

7 January 2021

Nontuberculous mycobacterial pulmonary infection in immunocompetent patients: comparison of thin-section CT and histopathologic findings.

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0538

7 January 2021

Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0538

7 January 2021

Treatment of sarcoidosis with infliximab

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0538

7 January 2021

Development of sarcoidosis during etanercept therapy

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0538

7 January 2021

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0538

7 January 2021

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0538

7 January 2021

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0538

7 January 2021

Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use.

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0538

7 January 2021

Experience with etanercept in an academic medical center: are infection rates increased?

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0538

7 January 2021

Reconsidering adjuvant immunotherapy for tuberculosis

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0538

7 January 2021

Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0538

7 January 2021

Infliximab for rheumatoid arthritis in a patient with tuberculosis

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0538

7 January 2021

Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0538

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0538

1 reference

14 May 2018

1 reference

14 May 2018